(509) 228-1000 WA
(208) 754-3100 ID

Medical Oncology and Hematology

A medical oncologist is a physician who has extensive training and experience in the diagnosis and treatment of cancer. As your primary cancer doctor, your medical oncologist and hematologist is actively involved in all levels of your care. He or she:

  • Educates you and your family about your form of cancer and its stages of development
  • Helps you explore and understand your treatment options
  • Oversees your chemotherapy and other treatments
  • Monitors your progress

Cancer Care Northwest offers complete medical oncology and hematology services, including:

Chemotherapy: Uses anticancer medicine to kill cancer. 

Immunotherapy: Uses medicines to boost your immune system's ability to fight cancer.  

Hormonal therapy: Reduces the level of hormones that some tumors need to grow.

Stem Cell Transplant: Replaces stem cells that were damaged during high-dose chemotherapy with your healthy stem cells.  

Targeted therapy: Uses drugs to target and directly attack cancer cells.  

Chemotherapy treatments are available at each of Cancer Care Northwest’s locations. Our medical oncology team includes eight board-certified, fellowship-trained physicians, nine nurse practitioners, and oncology nurses certified in chemotherapy administration. Our medical oncologists have extensive training and experience in the use of medicines and related medical procedures to fight cancer. They collaborate closely with other members of your care team—including your surgical oncologist and radiation oncologist—to ensure optimal results.

Clinical Trials

TRIAL NUMBER - NCT06120491

A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01).

TRIAL NUMBER - NCT06496178

A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma.

TRIAL NUMBER - NCT05952557

CAMBRIA-2: A Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease.

TRIAL NUMBER - 2021-05

Specimen Collection Study to Evaluate Biomarkers in Subjects with Cancer.

TRIAL NUMBER - NCT06072612

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.

TRIAL NUMBER - NCT06230185

Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients With Early Stage TNBC-Phase I (B-STRONGER-I).

TRIAL NUMBER - NCT05899608

A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (HARMONi-3).

TRIAL NUMBER - NCT05774951

A Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer.

TRIAL NUMBER - NCT05629585

A Phase 3 Open-label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy.

TRIAL NUMBER - NCT03526835

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors.

TRIAL NUMBER - THOR-1

A study to collect clinical as well as genomic data on lung cancer patients in order to improve our understanding of thoracic malignancies in our community as well as disparities that may affect patient access to treatment.

TRIAL NUMBER - NCT05563220

A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE).

TRIAL NUMBER - NCT05458674

A Phase II Study of the Safety, Tolerability and Antitumor Activity of Tucatinib in Combination With Eribulin and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer.

TRIAL NUMBER - NCT05211895

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8).

TRIAL NUMBER - NCT04510129

This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.